TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy
|Published in||Immunotherapy. 2018|
|Abstract||AIM: We evaluated a novel approach combining the use of attenuated Salmonella immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. MATERIALS & METHODS: B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated Salmonella enterica serovar Typhimurium LVR01. RESULTS: The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. CONCLUSION: Salmonella LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.|
|Keywords||Salmonella — Experimental model — Imiquimod — Immunotherapy — Melanoma|
This document has no fulltext available yet, but you can contact its author by using the form below.
|VOLA, Magdalena et al. TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy. In: Immunotherapy, 2018. doi: 10.2217/imt-2017-0188 https://archive-ouverte.unige.ch/unige:103449|